Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch Health Companies Inc.

www.bauschhealth.com

Latest From Bausch Health Companies Inc.

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.

Deals Business Strategies

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters

Bausch Sees Sales Drivers In Lumify, Ocuvite And PreserVision Line Extensions

Lumify reached 35% market share in US OTC eye drops and Ocuvite and Preservision vision health supplements are the No. 2 sales driver across Bausch's total portfolio.
OTC Drugs Dietary Supplements

Teva Fails To Unblock Route To Relistor Rival In US

A US district court has rejected Teva’s argument that a key US patent protecting Bausch’s Relistor methylnaltrexone-based constipation remedy is invalid and not infringed by its proposed generic.
Intellectual Property United States
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register